Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)—Polish compassionate use experience
نویسندگان
چکیده
منابع مشابه
Plerixafor in the Treatment of Stem Cell Mobilization Failure; First Experience in Iran
High-dose chemotherapy and autologous stem cell transplantation (SCT) have become an effective care for many patients with hematological malignancies. Harvesting the stem cells is one the most important parts of SCT. The two most commonly used mobilization regimens are the use of granulocyte colony-stimulating factor (G-CSF) or G-CSF plus chemotherapy. However, about 10-30% of patients are unab...
متن کاملPlerixafor in the Treatment of Stem Cell Mobilization Failure; First Experience in Iran
High-dose chemotherapy and autologous stem cell transplantation (SCT) have become an effective care for many patients with hematological malignancies. Harvesting the stem cells is one the most important parts of SCT. The two most commonly used mobilization regimens are the use of granulocyte colony-stimulating factor (G-CSF) or G-CSF plus chemotherapy. However, about 10-30% of patients are unab...
متن کاملPlerixafor use for peripheral blood stem cell mobilization in Korea
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Hematologic Malignancy Branch, National Cancer Center, Ilsan, Department of Internal Medicine, St. Mary Hospital, The Catholic University of Korea...
متن کاملPlerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
BACKGROUND The binding of CXCR4 with its ligand (stromal-derived factor-1) maintains hematopoietic stem/progenitor cells (HSPCs) in a quiescent state. We hypothesized that blocking CXCR4/SDF-1 interaction after hematopoietic stem cell transplantation (HSCT) promotes hematopoiesis by inducing HSC proliferation. METHODS We conducted a phase I/II trial of plerixafor on hematopoietic cell recover...
متن کاملplerixafor in the treatment of stem cell mobilization failure; first experience in iran
high-dose chemotherapy and autologous stem cell transplantation (sct) have become an effective care for many patients with hematological malignancies. harvesting the stem cells is one the most important parts of sct. the two most commonly used mobilization regimens are the use of granulocyte colony-stimulating factor (g-csf) or g-csf plus chemotherapy. however, about 10-30% of patients are unab...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Hematology
سال: 2010
ISSN: 0939-5555,1432-0584
DOI: 10.1007/s00277-010-1098-7